tradingkey.logo
搜索

Valneva SE

VALN
添加自选
5.680USD
-0.260-4.38%
收盘 05/15, 16:00美东报价延迟15分钟
545.56M总市值
亏损市盈率 TTM

Valneva SE

5.680
-0.260-4.38%

关于 Valneva SE 公司

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SE简介

公司代码VALN
公司名称Valneva SE
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
员工数量- -
证券类型Depository Receipt
年结日Jun 28
公司地址6, Rue Alain Bombard
城市SAINT-HERBLAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编44800
电话33228073710
网址https://valneva.com/
公司代码VALN
上市日期Jun 28, 2007
CEOLingelbach (Thomas)

Valneva SE公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--

收入明细

单位: USD更新时间: 4月6日 周一
单位: USD更新时间: 4月6日 周一
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
其他
6.77M
3.87%
地区USD
名称
营收
占比
United States
53.61M
30.69%
Canada
30.13M
17.25%
Germany
17.47M
10.00%
France
14.67M
8.40%
Nordics
13.90M
7.96%
其他
44.89M
25.70%
业务
地区
业务USD
名称
营收
占比
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
其他
6.77M
3.87%

股东统计

更新时间: 5月7日 周四
更新时间: 5月7日 周四
持股股东
股东类型
持股股东
持股股东
占比
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
其他
94.66%
持股股东
持股股东
占比
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
其他
94.66%
股东类型
持股股东
占比
Venture Capital
2.44%
Private Equity
2.42%
Investment Advisor
0.43%
Research Firm
0.17%
Hedge Fund
0.02%
其他
94.51%

机构持股

更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
36
5.21M
5.50%
-309.16K
2025Q4
32
5.27M
6.14%
+505.55K
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Novo Holdings A/S
2.31M
2.66%
-40.00K
-1.71%
Dec 31, 2025
Frazier Life Sciences Management, L.P.
2.29M
2.64%
--
--
Dec 31, 2025
General American Investors Company, Inc.
354.36K
0.41%
--
--
Dec 31, 2025
Wells Fargo Advisors
123.46K
0.14%
-30.53K
-19.82%
Dec 31, 2025
Morgan Stanley & Co. International Plc
32.26K
0.04%
+9.49K
+41.70%
Dec 31, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
--
--
Dec 31, 2025
Citadel Advisors LLC
23.49K
0.03%
+7.08K
+43.17%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
10.70K
0.01%
+500.00
+4.90%
Dec 31, 2025
XTX Markets LLC
10.63K
0.01%
+10.63K
--
Dec 31, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI